242 related articles for article (PubMed ID: 34307179)
1. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Passaro A; de Marinis F; Tu HY; Laktionov KK; Feng J; Poltoratskiy A; Zhao J; Tan EH; Gottfried M; Lee V; Kowalski D; Yang CT; Srinivasa BJ; Clementi L; Jalikop T; Huang DCL; Cseh A; Park K; Wu YL
Front Oncol; 2021; 11():709877. PubMed ID: 34307179
[TBL] [Abstract][Full Text] [Related]
2. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
Park K; Kim JS; Kim JH; Kim YC; Kim HG; Cho EK; Jin JY; Kim M; Märten A; Kang JH
BMC Cancer; 2021 Jul; 21(1):802. PubMed ID: 34253172
[TBL] [Abstract][Full Text] [Related]
3. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
de Marinis F; Laktionov KK; Poltoratskiy A; Egorova I; Hochmair M; Passaro A; Migliorino MR; Metro G; Gottfried M; Tsoi D; Ostoros G; Rizzato S; Mukhametshina GZ; Schumacher M; Novello S; Dziadziuszko R; Tang W; Clementi L; Cseh A; Kowalski D
Lung Cancer; 2021 Feb; 152():127-134. PubMed ID: 33387727
[TBL] [Abstract][Full Text] [Related]
4. A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
Tu HY; Feng J; Shi M; Zhao J; Wang Y; Chang J; Wang J; Cheng Y; Zhu J; Tan EH; Li K; Zhang Y; Lee V; Yang CT; Su WC; Lam DC; Srinivasa BJ; Rajappa S; Ho CL; Lam KC; Hu Y; Bondarde SA; Liu X; Tian Y; Xue Z; Cseh A; Huang DC; Zhou C; Wu YL
Target Oncol; 2022 Jan; 17(1):1-13. PubMed ID: 35020119
[TBL] [Abstract][Full Text] [Related]
5. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
7. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
9. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon
Jung HA; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33036377
[TBL] [Abstract][Full Text] [Related]
10. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Pham VL; Le TA; Pham CP; Hoa Nguyen TT; Do AT; Nguyen TK; Nguyen MH; Thu Hoang TA; Hao Vuong DT; Tam Nguyen DN; Khiem Dang V; Nguyen TO; Trang Vo TH; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Dung Nguyen K; Nguyen HG; Truong CM; Chau Pham TM; Nguyen TBP
Ther Adv Med Oncol; 2024; 16():17588359241242972. PubMed ID: 38736554
[TBL] [Abstract][Full Text] [Related]
11. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
[TBL] [Abstract][Full Text] [Related]
12. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
13. Afatinib 30 mg in the treatment of common and uncommon
Qian J; Ye X; Huang A; Qin R; Cai Y; Xue Y; Zhang S; Wang W; Xiong L; Gu A
J Thorac Dis; 2022 Jun; 14(6):2169-2177. PubMed ID: 35813735
[TBL] [Abstract][Full Text] [Related]
14. Sequential Afatinib and Osimertinib in Asian Patients with
Miura S; Jung HA; Lee SY; Lee SH; Lee MK; Lee YC; Hochmair MJ; Yang CT; Märten A; Yang JC; Popat S
Onco Targets Ther; 2022; 15():873-882. PubMed ID: 36033903
[TBL] [Abstract][Full Text] [Related]
15. Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon
Yang JC; Schuler M; Popat S; Miura S; Park K; Passaro A; De Marinis F; Solca F; Märten A; Kim ES
Front Oncol; 2022; 12():834704. PubMed ID: 35574304
[TBL] [Abstract][Full Text] [Related]
16. Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Fan Y; Chen J; Zhou C; Wang H; Shu Y; Zhang J; Hua H; Huang DC; Zhou C
Lung Cancer; 2020 Sep; 147():209-213. PubMed ID: 32738416
[TBL] [Abstract][Full Text] [Related]
17. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
18. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience of afatinib as first-line therapy for advanced
Lee SY; Choi CM; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park JY; Kim YC; Oh IJ; Jung CY; Lee SH; Yoon SH; Choi J; Jang TW
Transl Lung Cancer Res; 2021 Dec; 10(12):4353-4367. PubMed ID: 35070746
[TBL] [Abstract][Full Text] [Related]
20. Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation.
Dong W; Wang C; Wang C; Zhao K; Ma Z; Hu S
Front Oncol; 2022; 12():999606. PubMed ID: 36425553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
